Bavarian Nordic A/S is set to raise gross proceeds of DKK465 million (US$82 million) from a fully underwritten rights issue directed at current shareholders. (BioWorld International)

Bavarian Nordic A/S is set to raise gross proceeds of DKK465 million (US$82 million) from a fully underwritten rights issue directed at current shareholders. (BioWorld International)

Billing the investment as the largest venture capital round in German biotechnology since 2001, Immatics Biotechnologies GmbH raised €40 million (US$52.1 million) in a second funding round to further its pipeline of cancer vaccines based on peptides derived from tumor-associated antigens. (BioWorld International)

Billing the investment as the largest venture capital round in German biotechnology since 2001, Immatics Biotechnologies GmbH raised €40 million (US$52.1 million) in a second funding round to further its pipeline of cancer vaccines based on peptides derived from tumor-associated antigens. (BioWorld International)